Skip to content
Triangle logo TriangleGet started
← Full study record

NCT01592383 · ADVERSE EVENTS

Adverse events

Erlotinib Hydrochloride in Treating Patients With Malignant Peritoneal Mesothelioma · Source last updated 2018-10-16

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Adverse events occurred during the study; they are not necessarily caused by treatment. Serious events are not interchangeable with severe/grade 3–4 events. These safety populations may differ from efficacy populations.

Collection time frame
1 year
Other-event reporting threshold
0%

An expected mild skin rash

Participants affected / participants at risk, as reported
Safety groupSerious eventsOther eventsDeaths
Treatment (Enzyme Inhibitor Therapy)

Patients receive erlotinib hydrochloride PO QD. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.

0 / 21 / 20 / 2

Group identifiers: EG000: Treatment (Enzyme Inhibitor Therapy)

Serious adverse events

Event terms and counts are source-reported; expand to read more. A reporting threshold may omit less frequent events.

    Other reported adverse events

    Event terms and counts are source-reported; expand to read more. A reporting threshold may omit less frequent events.

    1. assessment Type
      NON_SYSTEMATIC_ASSESSMENT
      notes
      An expected mild skin rash
      organ System
      Skin and subcutaneous tissue disorders
      source Vocabulary
      NCI v4.01
      stats
      1. group Id
        EG000
        num Affected
        1
        num At Risk
        2
        num Events
        2
      term
      Rash maculo-papular
    2. assessment Type
      NON_SYSTEMATIC_ASSESSMENT
      organ System
      General disorders
      source Vocabulary
      NCI v4.01
      stats
      1. group Id
        EG000
        num Affected
        1
        num At Risk
        2
        num Events
        2
      term
      Fatigue
    3. assessment Type
      NON_SYSTEMATIC_ASSESSMENT
      organ System
      General disorders
      source Vocabulary
      NCI v4.01
      stats
      1. group Id
        EG000
        num Affected
        1
        num At Risk
        2
        num Events
        2
      term
      Constipation
    Complete source fields
    description
    An expected mild skin rash
    event Groups
    1. deaths Num Affected
      0
      deaths Num At Risk
      2
      description
      Patients receive erlotinib hydrochloride PO QD. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
      id
      EG000
      other Num Affected
      1
      other Num At Risk
      2
      serious Num Affected
      0
      serious Num At Risk
      2
      title
      Treatment (Enzyme Inhibitor Therapy)
    frequency Threshold
    0
    other Events
    1. assessment Type
      NON_SYSTEMATIC_ASSESSMENT
      notes
      An expected mild skin rash
      organ System
      Skin and subcutaneous tissue disorders
      source Vocabulary
      NCI v4.01
      stats
      1. group Id
        EG000
        num Affected
        1
        num At Risk
        2
        num Events
        2
      term
      Rash maculo-papular
    2. assessment Type
      NON_SYSTEMATIC_ASSESSMENT
      organ System
      General disorders
      source Vocabulary
      NCI v4.01
      stats
      1. group Id
        EG000
        num Affected
        1
        num At Risk
        2
        num Events
        2
      term
      Fatigue
    3. assessment Type
      NON_SYSTEMATIC_ASSESSMENT
      organ System
      General disorders
      source Vocabulary
      NCI v4.01
      stats
      1. group Id
        EG000
        num Affected
        1
        num At Risk
        2
        num Events
        2
      term
      Constipation
    time Frame
    1 year

    Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

    Preserved source evidence · Not medical advice